ClinicalTrials.gg
CompletedNCT07051252Updated Dec 12, 2025

A Study of HBS-201 (Pitolisant Delayed-release)

A Phase 1 interventional study of HBS-201 in Narcolepsy, sponsored by Harmony Biosciences Management, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 85 studies in Narcolepsy with a site in United States — 19 open to participants now, 20 under way, 8 of them phase 3. Narcolepsy · United States.

Enrollment
52nd of 69
46 · median 93
Started
2025
with 5 others
Phase 1
13 of 85
1 open now
Registered
75th of 85
by date
Lead sponsor
4 of 85
Harmony Biosciences Management, Inc.

Among the 85 studies in Narcolepsy with a site in United States, this one is the 52nd largest by enrollment of the 69 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 in phase 1, and was the 75th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

19 of the 85 studies in Narcolepsy with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Narcolepsy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy.

Read the detailed description

This is a Phase 1b, open-label, multicenter study to assess the tolerability of HBS-201 when starting at a therapeutic dose in adult participants with narcolepsy. Therapeutic dose range is defined as 17.8 milligram (mg) to 35.6 mg based on the FDA-approved prescribing information for WAKIX.

The study will consist of an up to 30-day Screening/Baseline Period, a 2-week Open-Label Period, and a 30-day Safety Follow-up Period.

03

Conditions studied

  • Narcolepsy

Browse trials for

Keywords

  • Narcolepsy
  • Pitolisant hydrochloride
  • Pitolisant delayed-release
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Has a current documented diagnosis of narcolepsy type 1 or narcolepsy type 2 per International Classification of Sleep Disorders, 3rd Edition (ICSD-3) criteria.

Exclusion criteria

Exclusion Criteria:

  1. Has hypersomnolence due to another medical disorder.
  2. Is currently taking or has taken WAKIX (pitolisant).
  3. Has participated in an interventional research study involving another medication, device, or behavioral treatment within 30 days or within 5 half-lives of the investigational medication prior to Screening.
  4. Based on the judgment of the Investigator, is unsuitable for the study for any reason, including but not limited to unstable or uncontrolled medical conditions (including psychiatric and neurological conditions) or a medical condition that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the participant, or compromise the integrity of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    HBS-201

    Participants will take HBS-201 orally once daily in the morning upon wakening, beginning the morning of Day 1 and continuing through Day 14.

    Drug: HBS-201

Interventions

  • DrugHBS-201

    On Days 1-7, participants will take HBS-201 17.8 mg per day (one 17.8 mg tablet) and on Days 8-14, participants will take HBS-201 35.6 mg per day (two 17.8 mg tablets).

    Also known as: pitolisant delayed-release (DR), pitolisant hydrochloride

06

What researchers measure

Primary outcomes

  1. Percentage of participants who discontinue treatment due to a treatment-emergent adverse event (TEAE) related to study drug

    A TEAE is any adverse event (AE) reported after the first dose of study drug, or any worsening of a pre-existing condition reported after first dose of study drug.

    Time frame: From administration of the first dose of study drug (Day 1) through 30 days after the final dose of study drug, approximately 44 days

  2. Frequency, severity, and seriousness of TEAEs

    A TEAE is any adverse event (AE) reported after the first dose of study drug, or any worsening of a pre-existing condition reported after first dose of study drug.

    Time frame: From administration of the first dose of study drug (Day 1) through 30 days after the final dose of study drug, approximately 44 days

07

Study locations

15 sites
  • Harmony Site 9
    San Ramon, California 94583, United States
  • Harmony Site 14
    Brandon, Florida 33511, United States
  • Harmony Site 4
    Miami, Florida 33176, United States
  • Harmony Site 8
    Atlanta, Georgia 30328, United States
  • Harmony Site 13
    Newton, Massachusetts 02459, United States
  • Harmony Site 11
    Troy, Michigan 48085, United States
  • Harmony Site 10
    Denver, North Carolina 28037, United States
  • Harmony Site 2
    Huntersville, North Carolina 28078, United States
  • Harmony Site 6
    Canton, Ohio 44718, United States
  • Harmony Site 1
    Cincinnati, Ohio 45245, United States
  • Harmony Site 15
    Wyomissing, Pennsylvania 19610, United States
  • Harmony Site 5
    Columbia, South Carolina 29201, United States
  • Harmony Site 12
    North Charleston, South Carolina 29406, United States
  • Harmony Site 3
    Austin, Texas 78731, United States
  • Harmony Site 7
    Morgantown, West Virginia 26506, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Oct 2025, 4 months.

Of 13 phase 1 interventional studies under Narcolepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 4, 2025
StartActual
May 21, 2025
Primary completionActual
Oct 13, 2025
CompletionActual
Oct 13, 2025
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051252
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
May 21, 2025
Primary completion
Oct 13, 2025
Completion
Oct 13, 2025
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion